Company intelligence / Profile preview

GEN

South San Francisco, California, United Statesgendigital.com ↗

Ownership: Public · GEN
Employees: ~13500
Development stage: Commercial

Overview

Genentech pioneered recombinant DNA technology with first-in-class products like synthetic human insulin. It has developed numerous blockbuster drugs such as trastuzumab (Herceptin), bevacizumab (Avastin), rituximab (Rituxan), and ocrelizumab (Ocrevus). The company continues to advance therapies across oncology, immunology, neuroscience, ophthalmology and rare diseases with a robust clinical pipeline at all stages.

Therapeutic areas: OncologyNeurology
Modalities: Monoclonal antibodySmall moleculeAntibody-drug conjugateProtein
Industry: Pharma

Partnerships

Novartis (co-development/commercialization e.g., Xolair)City of Hope Medical CenterEli Lilly & Co. (licensed Humulin from Genentech's technology)

Financials

Market cap: $17.8B
Total revenue: $1.3B
Enterprise value: $25.5B

Beyond the preview

Go deeper on GEN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GEN.

Explore the full profile